Shares of Context Therapeutics Inc. (NASDAQ:CNTX – Get Free Report) shot up 0.3% during trading on Monday. The stock traded as high as $0.3082 and last traded at $0.3050. 503,255 shares were traded during trading, a decline of 54% from the average daily volume of 1,089,709 shares. The stock had previously closed at $0.3042.
Analyst Ratings Changes
A number of equities analysts have commented on the stock. Zacks Research cut shares of Context Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday. Lifesci Capital cut shares of Context Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. Maxim Group decreased their target price on shares of Context Therapeutics from $8.00 to $4.00 and set a “buy” rating on the stock in a research report on Tuesday, June 16th. Wall Street Zen downgraded shares of Context Therapeutics from a “sell” rating to a “strong sell” rating in a report on Monday, July 20th. Finally, Citigroup reiterated an “outperform” rating on shares of Context Therapeutics in a research report on Thursday, August 6th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Context Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $6.17.
Check Out Our Latest Report on CNTX
Context Therapeutics Stock Performance
Context Therapeutics (NASDAQ:CNTX – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.06). As a group, equities analysts anticipate that Context Therapeutics Inc. will post -0.45 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of CNTX. Squarepoint Ops LLC bought a new stake in shares of Context Therapeutics in the 2nd quarter worth about $29,000. Two Sigma Securities LLC boosted its stake in shares of Context Therapeutics by 388.7% during the 2nd quarter. Two Sigma Securities LLC now owns 61,444 shares of the company’s stock worth $34,000 after purchasing an additional 48,871 shares during the period. Bank of America Corp DE purchased a new position in shares of Context Therapeutics during the 2nd quarter worth about $30,000. ADAR1 Capital Management LLC bought a new position in Context Therapeutics during the 2nd quarter valued at about $416,000. Finally, Clear Harbor Asset Management LLC bought a new position in Context Therapeutics during the 2nd quarter valued at about $51,000. Institutional investors own 14.03% of the company’s stock.
About Context Therapeutics
Context Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing targeted treatments for solid tumors, with an emphasis on therapies designed to address cancers with limited treatment options. The company is headquartered in Philadelphia, Pennsylvania, and its activities are centered on the discovery and clinical development of oncology medicines.
Context’s lead program is CTIM-76, an investigational bispecific T-cell engager designed to bind Claudin 6 (CLDN6) on tumor cells and CD3 on T cells.
Read More
- Five stocks we like better than Context Therapeutics
- Tesla Wants to Make Its Own Chips—What Could Go Wrong?
- IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver?
- PBF Energy’s Stunning Rally Faces a Critical Test
- Citi Stock Falls Despite Earnings Beat: What Investors Need to Know
Receive News & Ratings for Context Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Context Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
